Barclays’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-6,125
| Closed | -$23K | – | 7582 |
|
|
2017
Q4 | $23K | Sell |
6,125
-8,875
| -59% | -$36.3K | ﹤0.01% | 6241 |
|
|
2017
Q3 | $61K | Buy |
15,000
+14,969
| +48,287% | +$57.3K | ﹤0.01% | 5243 |
|
|
2017
Q2 | $0 | Sell |
31
-29,133
| -100% | -$116K | ﹤0.01% | 7169 |
|
|
2017
Q1 | $120K | Buy |
29,164
+27,172
| +1,364% | +$114K | ﹤0.01% | 4762 |
|
|
2016
Q4 | $9K | Buy |
1,992
+1,523
| +325% | +$9.85K | ﹤0.01% | 5962 |
|
|
2016
Q3 | $5K | Sell |
469
-3,258
| -87% | -$23.1K | ﹤0.01% | 6040 |
|
|
2016
Q2 | $21K | Buy |
3,727
+2,120
| +132% | +$14.4K | ﹤0.01% | 5262 |
|
|
2016
Q1 | $9K | Buy |
1,607
+1,140
| +244% | +$8.78K | ﹤0.01% | 5522 |
|
|
2015
Q4 | $6K | Buy |
467
+384
| +463% | +$6.61K | ﹤0.01% | 5546 |
|
|
2015
Q3 | $1K | Sell |
83
-4,036
| -98% | -$82.7K | ﹤0.01% | 6723 |
|
|
2015
Q2 | $73K | Buy |
4,119
+2,697
| +190% | +$42.7K | ﹤0.01% | 4903 |
|
|
2015
Q1 | $9K | Buy |
1,422
+323
| +29% | +$3.17K | ﹤0.01% | 6307 |
|
|
2014
Q4 | $7K | Sell |
1,099
-1,264
| -53% | -$13.7K | ﹤0.01% | 6902 |
|
|
2014
Q3 | $14K | Buy |
2,363
+229
| +11% | +$3.5K | ﹤0.01% | 6717 |
|
|
2014
Q2 | $39K | Sell |
2,134
-47
| -2% | -$829 | ﹤0.01% | 6119 |
|
|
2014
Q1 | $26K | Buy |
2,181
+1,256
| +136% | +$20.6K | ﹤0.01% | 6462 |
|
|
2013
Q4 | $5K | Buy |
925
+661
| +250% | +$7.39K | ﹤0.01% | 7188 |
|
|
2013
Q3 | $3K | Sell |
264
-13,066
| -98% | -$138K | ﹤0.01% | 7144 |
|
|
2013
Q2 | $126K | Buy |
+13,330
| New | +$171K | ﹤0.01% | 5601 |
|
Barclays's CASC Position: Q1 2018 in Review
Barclays sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 6,125 shares — an estimated $23K sold.
Barclays first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $126K in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Barclays reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Barclays sold 6,125 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $23K.
- Barclays first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Cascadian Therapeutics, Inc. position peaked at $126K in Q2 2013.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.